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Abstract
 
The linker for activation of T cells (LAT) is an adaptor protein critical for Fc
 
 
 
RI-mediated
mast cell activation. LAT is a substrate of the tyrosine kinases activated after TCR and Fc
 
 
 
RI
engagement. After phosphorylation of the cytosolic domain of LAT, multiple signaling mole-
cules such as phospholipase C–
 
 
 
1, Grb2, and Gads associate with phosphorylated LAT via their
SH2 domains. The essential role of the four distal tyrosines in TCR-mediated signaling and T
cell development has been demonstrated by experiments using LAT-deficient cell lines and
genetically modified mice. To investigate the role of these four tyrosines of LAT in Fc
 
 
 
RI-
mediated mast cell activation, bone marrow–derived mast cells from LAT-deficient mice were
infected with retroviral vectors designed to express wild-type or mutant LAT. Examination of
bone marrow–derived mast cells expressing various tyrosine to phenylalanine mutants in LAT
demonstrates a differential requirement for these different binding sites. In these studies, assays
of biochemical pathways, degranulation, and cytokine and chemokine release were performed.
Finally, the role of these tyrosines was also evaluated in vivo using genetically modified ani-
mals. Deletion of all four distal tyrosines, and in particular, loss of the primary phospholipase
C–
 
 
 
-binding tyrosine had a significant effect on antigen-induced histamine release.
Key words: signal transduction • adapter molecules • phosphorylation • Fc epsilon receptor • 
anaphylaxis
 
Introduction
 
Aggregation of the high affinity receptor for IgE (Fc
 
 
 
RI)
on mast cells leads, via a complex set of biochemical events,
to activation of a number of mast cell effector functions.
These include release of granules containing histamine, sero-
tonin, 
 
 
 
-hexosaminidase, and mast cell–specific proteases.
Additionally, transcription of multiple cytokine and che-
mokine genes and secretion of these proteins also follows re-
ceptor engagement. Among the cytokines, interleukins
1–6, 9, 10, 13, 16, TNF-
 
 
 
, TGF-
 
 
 
, and GM-CSF are known
to be produced in response to Fc
 
 
 
RI stimulation. The che-
mokines MCP-1, MIP-1
 
 
 
, MIP-1
 
 
 
, and regulated on acti-
vation, normal T cell–expressed and secreted (RANTES)
are also produced in response to Fc
 
 
 
RI stimulation. A ma-
jor question in the study of Fc
 
 
 
RI-mediated signaling is
how the early biochemical events after Fc
 
 
 
RI engagement
lead ultimately to granule release and gene transcription (1).
The Fc
 
 
 
RI is comprised of multiple subunits, a ligand-
binding 
 
 
 
 chain, and two chains, 
 
 
 
 and 
 
 
 
, which function
as signal transduction subunits (2). Both of these subunits
contain an immunoreceptor tyrosine-based activation motif
(ITAM), containing paired tyrosine residues (3). Engage-
ment of this receptor with IgE and polyvalent antigen leads
to activation of several Src family protein tyrosine kinases
(PTKs). One of these, Lyn, phosphorylates the cytosolic tyro-
sines of the 
 
 
 
 and 
 
 
 
 ITAMs (4–6). These phosphorylations
create a binding site for the tandem SH2 domains of Syk
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Abbreviations used in this paper:
 
 BMMC, bone marrow–derived mast cells;
HRP, horseradish peroxidase; IRES, internal ribosomal entry site; ITAM,
immunoreceptor tyrosine-based activation motif; LAT, linker for activation
of T cells; MAP, mitogen-activated protein; MBP, myelin basic protein;
PLC, phospholipase C; PTK, protein tyrosine kinase; RANTES, regulated
on activation, normal T cell–expressed and secreted; WT, wild type.T
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PTK. Interaction of Syk with the phosphorylated ITAMs
also activates this enzyme. Syk is known to be a crucial
molecule for Fc
 
 
 
RI signaling because Syk-deficient mast
cells fail to activate any downstream pathways after Fc
 
 
 
RI
engagement (7, 8).
Activation of Syk leads to phosphorylation of at least one
important adaptor molecule, the linker for activation of T
cells (LAT; reference 9). When phosphorylated, LAT re-
cruits a number of important signaling molecules contain-
ing SH2 domains. From works in T cells as well as mast
cells, it is known that the LAT-binding proteins include
but are not limited to the additional adapters, Grb-2 and
Gads (9–11). In turn, these proteins are bound to SOS and
SLP-76, respectively. In addition, phosphorylated LAT
recruits the enzymes phospholipase C (PLC)–
 
 
 
1 and PLC-
 
 
 
2. From this limited list, it is clear that the phosphoryla-
tion of LAT leads to recruitment of molecules that are cen-
tral to activation of small G-proteins (SOS) and to control
calcium flux, diacylglycerol production, and activation of
protein kinase C (PLC isoforms; reference 12).
The importance of LAT in mast cell function has been
revealed in gene inactivation studies. Bone marrow–derived
mast cells (BMMCs) from LAT-deficient mice demon-
strated severe defects of mast cell function (13). Mast cell
degranulation and transcription of multiple cytokine genes
was markedly impaired in these studies. Based on work in T
cells, it is likely that the distal four tyrosine residues of LAT
mediate important LAT-binding events (10). To investigate
whether these residues are critical to mast cell function and
to determine how various signaling molecules couple to
LAT, we reconstituted the function of LAT-deficient BMMCs.
Various LAT mutants were introduced into these cells using
Moloney murine leukemia retroviral constructs. Addition-
ally, in vivo studies were performed using mice expressing
genetically targeted mutations in LAT.
There was no difference in Fc
 
 
 
RI-mediated mast cell ac-
tivation between BMMCs from LAT
 
 
 
/
 
 
 
 mice and the
BMMCs from LAT 
 
 
 
/
 
 
 
 mice reconstituted with wild-type
LAT. There was also no difference in Fc
 
 
 
RI-mediated mast
cell activation between BMMCs from LAT
 
 
 
/
 
 
 
 mice and
the BMMCs from LAT
 
 
 
/
 
 
 
 mice that expressed a mutant
LAT in which all four distal tyrosines were converted to
phenylalanines. These results demonstrate that the four dis-
tal tyrosines are critical for LAT-dependent signaling in mast
cells after Fc
 
 
 
RI engagement. BMMCs expressing single or
combination mutations of LAT demonstrated a differential
requirement for the various LAT residues, with the primary
PLC-binding site being the most important. The in vivo
studies confirmed the critical role of LAT for histamine re-
lease. The four distal LAT tyrosines and the principal PLC
site are required in this in vivo response to antigen.
 
Materials and Methods
 
Mice.
 
Generation of LAT-deficient mice was reported previ-
ously (14). Mice were caged in a specific pathogen-free environ-
ment in accordance with National Institutes of Health regula-
 
tions. All mice were of a C57/BL6 and 129/Sv–mixed
background.
 
Construction of LAT Mutants.
 
Mouse LAT tyrosine to phenyl-
alanine mutations were made using the Quickchange mutagene-
sis kit (Stratagene). A NcoI site was made in the start codon of
LAT for cloning. Mutations were confirmed by DNA sequenc-
ing. The retroviral expression vector used was pMX-puro, which
is a chimeric vector of pBabe and MFG (a gift from T. Kitamura,
University of Tokyo, Tokyo, Japan). The encephalomyocarditis
virus internal ribosomal entry site (IRES) isolated from pCITE-2a
was used for bicistronic expression (15). The IRES-EGFP was
subcloned at the BamHI and NotI sites of pBluescript. Wild-type
or mutant LAT cDNA (a gift from S. Habu, Tokai University
School of Medicine, Isehara, Japan) were subcloned downstream
of the IRES at the NcoI and NotI sites of this construct. Trun-
cated rat CD2 cDNA with extracellular, transmembrane, and
three amino acids of the cytoplasmic region was subcloned up-
stream of IRES at the SmaI site of this construct. These con-
structs were digested with XhoI and NotI to make CD2-IRES-
LAT as shown in Fig. 1. After treatment with Klenow fragment,
these fragments were subcloned into the pMX-puro vector.
 
Retrovirus Infection and Mast Cell Isolation.
 
Bone marrow cells
taken from LAT
 
 
 
/
 
 
 
 and LAT
 
 
 
/
 
 
 
 mouse femurs were incubated in
suspension culture in the presence of IL-3 for 4–8 wk. Phoenix E
and Bosc 23 were used as packaging cell lines (16). At 24 h before
transfection, Phoenix E and Bosc 23 cells were mixed at a 1:9 ra-
tio. Retroviral vectors were transfected into these cells using Lipo-
fectamine Plus (Invitrogen). For retroviral infection, LAT
 
 
 
/
 
 
 
BMMCs cultured for 12 d were mixed with the packaging cell
lines transfected with vectors. After 48 h of the mixed culture, the
BMMCs were harvested and cultured in IL-3–containing me-
dium. 2 d later, the infection efficiency was measured by anti–rat
CD2 staining. 25–30% of the BMMCs were positive for rat CD2.
After 2 wk of subsequent puromycin selection, the BMMCs were
stained with anti–rat CD2 and IgE 
 
 
 
 anti-IgE–FITC to confirm
expression of LAT protein and to measure the mast cell purity.
Mast cell granules were stained with toludine blue.
 
Flow Cytometric Analysis of IgE Receptor, Rat CD2, and LAT
Expression.
 
BMMCs were preincubated with 5 
 
 
 
g/ml anti-
CD16/CD32 (2.4G2; BD Biosciences) and stained for Fc
 
 
 
RI
with 2.5 
 
 
 
g/ml anti-DNP IgE (SPE-7 mAb; Sigma-Aldrich), fol-
lowed by FITC-conjugated rat anti–mouse IgE (BD Biosciences).
To detect rat CD2 expression level, BMMCs were treated with
FITC-conjugated anti–rat CD2 antibody or FITC-conjugated
IgG (BD Biosciences) as a negative control. To detect LAT ex-
pression level, BMMCs were fixed with 3.7% paraformaldehyde
for 30 min at room temperature and treated with 0.1% Triton
X-100 for 4 min. After blocking with 2% goat serum, the
BMMCs were stained with rabbit anti-LAT and phycoerythrin-
conjugated goat anti–rabbit antibody. FACScan™ (Becton Dick-
inson) was used for the analysis of stained cells.
 
Cell Stimulation, Immunoblotting, and Immunoprecipitation.
 
Cells
were preloaded for at least 4 h with 1 
 
 
 
g/ml anti-DNP IgE
(17) in medium (without IL-3). Cells were challenged in Ty-
rode’s buffer with 100 ng/ml DNP-HSA (13). Before immuno-
precipitation, cells were lysed in buffer containing 150 mM
NaCl, 50 mM Tris-HCl, pH 7.6, 4 mM EGTA, 20 
 
 
 
g/ml pep-
statin, complete inhibitor cocktail tablets (Roche), 1% Brij or
NP-40, 1% 
 
n
 
-octyl-
 
 
 
-
 
d
 
-glucoside, 1 mM sodium orthovanadate,
7 mM EDTA for 30 min on ice. The lysis buffer for SLP-76 im-
munoprecipitation was 150 mM NaCl, 25 mM Tris-HCl, pH
7.6, 4 mM EGTA, 40 
 
 
 
g/ml Bestatin, 2 
 
 
 
g/ml E64, 2.5 
 
 
 
g/ml
macroglobulin, 10 
 
 
 
g/ml phosphoramidon, 30 
 
 
 
g/ml pepstatin,T
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complete inhibitor cocktail tablets, 1% Triton X-100, 1%
 
n
 
-octyl-
 
 
 
-
 
d
 
-glucoside, 1 mM sodium orthovanadate, 7 mM
EDTA. Antibodies used for immunoprecipitation were anti-LAT
antiserum (9), anti–PLC-
 
 
 
 1 (Upstate Biotechnology), anti-Grb2
and anti–PLC-
 
 
 
2 (Santa Cruz Biotechnology, Inc.), and anti–
SLP-76 (Antibody Solutions). Antibodies used for immunoblot-
ting were 4G10 and SLP-76 (Upstate Biotechnology). Reagents
used for detection of antibody in immunoblots were protein
A–horseradish peroxidase (HRP) and sheep anti–mouse IgG-
HRP (Amersham Biosciences), and protein A/protein G–HRP
(Pierce Chemical Co.).
 
Measurement of Calcium Flux and Degranulation.
 
Cells were
preloaded with 1 
 
 
 
g/ml anti-DNP IgE at 37
 
 
 
C for 4 h. The cells
were incubated with 16 
 
 
 
M Fluo-4–AM and 16 
 
 
 
M Fura red in
2% FCS RPMI 1640 medium at 37
 
 
 
C for 45 min. The cells were
washed twice with Tyrode’s buffer, resuspended, and kept at room
temperature for 30 min to allow cleavage of the AM esters. The
cells were analyzed by FACScan™ (Becton Dickinson). Intracellu-
lar calcium concentration is shown as the Fluo-4/Fura red fluores-
cence intensity ratio. Degranulation was determined by measuring
the release of 
 
 
 
-hexosaminidase as described previously (13).
 
Mitogen-activated Protein (MAP) Kinase Assay.
 
For ERK and
JNK kinase assays, cells were preloaded for 4 h with 1 
 
 
 
g/ml
anti-DNP IgE in medium (without IL-3) and stimulated with
100 ng/ml DNP-HSA for 8 or 10 min. For ERK kinase assays,
ERK2 immunoprecipitated with rabbit polyclonal serum against
ERK2 (Santa Cruz Biotechnology, Inc.) was used to phosphory-
late myelin basic protein (MBP; Upstate Biotechnology) for 10
min at room temperature. For JNK assays, JNK1 immunoprecip-
itated with rabbit polyclonal serum against JNK1 (Santa Cruz
Biotechnology, Inc.) was used to phosphorylate the GST-Jun
5–89 fusion protein (c-Jun–GST; Upstate Biotechnology) for 10
min at room temperature. To control for JNK1 levels, this mem-
brane was cut and immunoblotted with anti-JNK1. To detect
phosphorylated p38 MAP kinase, cells were preloaded for 4 h
with 1 
 
 
 
g/ml anti-DNP IgE in medium (without IL-3) and stim-
ulated with 100 ng/ml DNP-HSA for 5 and 10 min. Total cell
lysates for immunoblotting were prepared by boiling in reducing
sample buffer, and were separated on a 4–15% acrylamide gel by
PAGE. The membrane was immunoblotted with anti–phospho-
p38 antibody (New England BioLabs, Inc.). After stripping, the
membrane was reblotted with anti-p38 antibody (Santa Cruz
Biotechnology, Inc.).
 
RT-PCR.
 
(2 
 
 
 
 10
 
6
 
 cells were preincubated with 1 
 
 
 
g/ml of
DNP-specific IgE at 3 
 
  
 
10
 
6
 
 cells/ml for at least 4 h. Cells were
washed three times and stimulated with 100 ng/ml DNP-HSA
for 1 h. Total RNA was isolated using the TRI reagent (Molecu-
lar Research Center; reference 13). First strand cDNA synthesis
was performed using the Superscript RT-PCR kit (Life Technol-
ogies). 2.5 
 
 
 
g total RNA was used in reactions primed with oligo
dT to obtain cDNA. 7.5 
 
 
 
l of the synthesized cDNA in 150 
 
 
 
l
dH
 
2
 
0 was used as the template for the cytokine mRNA amplifi-
cation reactions. PCR conditions were as follows: 94
 
 
 
C for 5
min, 30 cycles for 94
 
 
 
C for 30 s, 57
 
 
 
C for 30 s, 72
 
 
 
C for 1 min,
72
 
 
 
C for 8 min, and soak at 4
 
 
 
C. Primers for IL-2 were obtained
from Ambion and primers for GAPDH, used as an internal con-
trol, were obtained from CLONTECH Laboratories, Inc.
 
RNase Protection Assay.
 
The Multiprobe RNase Protection
Assay was performed according to the manufacturer’s (BD Bio-
sciences) directions with modifications as follows.
For hybridization, probes were synthesized with [
 
33
 
P]UTP (70–
80 
 
 
 
C/full reaction) using the BD Biosciences In Vitro Transcrip-
tion kit. Probes were purified by gel filtration. 0.5–1.0 
 
 
 
 10
 
6
 
 cpm
was added to each RNA in a final hybridization volume of 10–20
 
 
 
l (at least 50% BD Biosciences hybridization buffer).
For the RNase inactivation, a master cocktail containing 200
 
 
 
l RNase inactivation reagent (Ambion), 50 
 
 
 
l ethanol, 5 
 
 
 
g
yeast tRNA, and 1 
 
 
 
l GycoBlue coprecipitate per RNA sample
was used to precipitate the protected RNA (Ambion). Pellets
were resuspended in 3 
 
 
 
l of sample buffer before electrophoresis
(BD Biosciences).
 
Passive Systemic Anaphylaxis.
 
Mice were sensitized with intra-
venous anti-DNP IgE as described previously (13). They were
subsequently pseudochallenged by intravenous injection of saline
or challenged with either DNP-HSA or 200  g anti-IgE for 1.5
min, killed with CO2, and blood was obtained immediately by
cardiac puncture. Serum histamine levels were assayed using a
competitive histamine immunoassay.
Results
Introduction of LAT Mutants into LAT-deficient BMMCs by
Retroviral Infection. We demonstrated previously that LAT
was essential for Fc RI-mediated mast cell activation (13).
Mast cell activation after Fc RI engagement was signifi-
cantly reduced in LAT-deficient BMMCs. Tyrosine phos-
phorylation of PLC- 1, PLC- 2, and SLP-76, calcium
mobilization, degranulation, and cytokine expression were
significantly reduced in LAT-deficient mast cells. As shown
in Fig. 1 A, the cytosolic domain of LAT contains nine ty-
rosines. Of the four distal tyrosines, tyrosine 136 (YLVV) is
in a potential PLC- 1–binding motif and tyrosines 175
(YVNV), 195 (YVNV), and 235 (YENL) form classical
Grb2-binding motifs (YXN). In T cells, these four distal
tyrosines are critical for TCR signaling and T cell differen-
tiation in the thymus (10, 18). To investigate the role of
the tyrosines of LAT in mast cells, various LAT mutants
were introduced into a Moloney murine leukemia virus
vector, pMX-puro (Fig. 1 B; reference 19). This retroviral
vector was designed for the bicistronic expression of two
products. The first is LAT wild type (LAT-WT) or mutant
forms of LAT containing tyrosine to phenylalanine muta-
tions. The second, used as a surface marker to detect suc-
cessfully infected BMMCs, is truncated rat CD2 containing
normal extracellular and transmembrane domains and 3
amino acids of the cytoplasmic domain (15). The encepha-
lomyocarditis virus IRES was used to ensure bicistronic ex-
pression. In preliminary experiments, the cDNA of LAT-
WT was inserted upstream and the cDNA of truncated rat
CD2 was inserted downstream of IRES. With this con-
struct, the infected BMMCs expressed LAT at levels  10-
fold higher than that found in normal LAT /  BMMCs as
determined by flow cytometry and blotting experiments
using the anti-LAT antibody (unpublished data). We re-
versed the order of the two DNAs in the vector. The
cDNA of LAT was inserted downstream of the IRES and
the cDNA for truncated rat CD2 was inserted upstream of
the IRES in an attempt to induce lower expression of LAT
molecules, because IRES-dependent translation is generally
less efficient (20). This change resulted in LAT expression
level in the infected BMMCs that was about twofold
higher than that expressed in normal LAT /  BMMCs (seeT
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Fig. 2, C and D). Different LAT cDNAs with specific mu-
tations shown previously to effect T cell activation were
inserted downstream of the IRES (10). One cDNA con-
tained the single replacement of the potential PLC- 1–
binding site, Tyr 136 (LAT-1YF). The second cDNA con-
tained a double replacement of both tyrosines 175 and 195,
which in the sequence context YVNV both form Grb2-
binding sites (LAT-2YF). Mutation of these two tyrosines
plus Tyr 235, which also is part of a potential Grb2-binding
site (YENL), created the third cDNA (LAT-3YF). Finally,
the mutation of all four of these tyrosines was made and in-
serted (LAT-4YF; Fig. 1 B).
These retroviral constructs as well as a construct lacking
any LAT cDNA were individually transfected into mixed
cultures of two retrovirus producing cell lines, Bosc 23
and Phoenix E. 16 h later, these transfected cells were
mixed with LAT /  BMMCs cultured for 12 d in me-
dium containing IL-3. After 48 h of this combined cul-
ture, the infection efficiency, determined by expression of
CD2 was  20%, an efficiency greater than when Bosc 23
or Phoenix E cells were used separately, or when culture
supernatants were used. After puromycin selection for  2
wk, the infected LAT /  BMMCs were stained with anti–
rat CD2 antibody. Almost 100% of infected BMMCs ex-
pressed rat CD2 at the same level, regardless of which con-
struct was used (Fig. 2 A). The cells were also assayed for
Fc RI expression levels, and receptor levels on the
BMMCs after retroviral expression was identical to that of
either LAT /  or LAT /  BMMCs (Fig. 2 B). Cells from
each of the infected BMMCs contained almost equivalent
numbers of toluidine-positive granules, indicating normal
mast cell morphology (unpublished data). LAT expression
levels in the infected LAT /  BMMCs were assayed by
flow cytometry and blotting with the anti-LAT antibody.
Both approaches demonstrated that LAT expression levels
in all of the infected BMMCs was about twofold higher
than that in LAT /  BMMCs (Fig. 2, C and D). Infected
LAT /  BMMCs were generated repeatedly with the
same level of CD2 and LAT expression and were used for
biochemical and functional analyses of mast cells after
Fc RI engagement.
Tyrosine Phosphorylation of LAT after Fc RI Engagement.
Tyrosine phosphorylation of LAT is critical for LAT func-
tion. To analyze whether various tyrosine mutations of
LAT molecules expressed in infected LAT /  BMMCs
could be tyrosine-phosphorylated after Fc RI engagement,
the infected BMMCs were sensitized by incubation with
monoclonal anti-DNP IgE and were stimulated with 100
ng/ml DNP-HSA for 1 min. Tyrosine phosphorylation of
LAT was maximal at 30 s–2 min after stimulation (13).
Wild-type and mutant LAT molecules were immunopre-
cipitated with anti-LAT antibody, and tyrosine phosphory-
lation was detected by antiphosphotyrosine blotting. As
shown in Fig. 3 A, the LAT-WT molecule expressed in in-
fected LAT /  BMMCs was phosphorylated at a level sim-
ilar to endogenous LAT phosphorylation in LAT / 
BMMCs. Mutation of Y136 (LAT-1YF) had a minimal
effect on phosphorylation, though consistently levels of
phosphorylation were less than with LAT-WT. Phosphor-
ylation of the LAT-2YF molecule was decreased, and mu-
tation of all three Grb2-binding sites had a dramatic effect
on the level of phosphorylation. Finally, mutation of all
four distal tyrosines, LAT-4YF, almost entirely inhibited
phosphorylation of the molecule. The results demonstrate
that the four distal tyrosines are the major phosphorylation
sites of LAT in mast cells.
Association of Grb2 with LAT. Phosphorylated LAT is
associated with multiple signaling molecules, including the
adaptor molecule Grb2. LAT has several potential Grb2-
binding sites as described in Fig. 1. To analyze the Grb2 as-
sociation with LAT in the reconstituted LAT /  BMMCs,
activated cells were lysed, WT or mutant LAT molecules
were immunoprecipitated with anti-LAT antibody, and
Grb2 association was detected by anti-Grb2 blotting. As
Figure 1. (A) Schematic representation of the mouse LAT molecule. Y
denotes tyrosine residues that are potential phosphorylation sites. Y136
(YLVV) is the predicted PLC- 1–binding site. Y175 and Y195 (YVNV)
and 235 (YENL) are the predicted Grb2-binding sites. (B) Retroviral
constructions used for coexpression of rat CD2 and LAT in transduced
LAT /  BMMCs. Domains include extracellular (EC), transmembrane
(TM), and cytoplasmic (CY). Viruses expressing CD2 alone (CD2-
IRES); CD2 with wild-type LAT (CD2-IRES-LAT-WT); the Y136 F
mutation (CD2-IRES-LAT-1YF); Y175F and Y195 F mutations (CD2-
IRES-LAT-2YF); Y175 F, Y195 F, and Y235 F mutations (CD2-IRES-
LAT-3YF); and Y136 F, Y175 F, Y195 F, and Y235 F mutations (CD2-
IRES-LAT-4YF) were used to transduce LAT /  BMMCs.T
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shown in Fig. 3 A, the level of association between the
LAT-WT molecule expressed in LAT /  BMMCs and
Grb2 was comparable to that of endogenous LAT and
Grb2 in activated LAT /  BMMCs. The amount of Grb2
associated with LAT-1YF was actually higher than that ob-
served with the LAT-WT and Grb2 association. The asso-
ciation of Grb2 with LAT-2YF was markedly depressed,
and neither LAT-3YF nor LAT-4YF showed any interac-
tion with Grb2. Reciprocal Grb2 immunoprecipitation ex-
periments supported these results. LAT-WT and LAT-1YF
molecules were coprecipitated with the anti-Grb2 antibody
from activated cells. However, in this experiment, LAT-
2YF did not coprecipitate with Grb2 (unpublished data).
These results all demonstrate that the predicted Grb2-bind-
ing sites, tyrosines 175, 195, and 235 are, in fact, essential
for Grb2 and LAT association.
PLC- 1– and Grb2-binding Binding to LAT Are Essential
for the Tyrosine Phosphorylation of PLC- 1 and PLC- 2.
Previously, we demonstrated that LAT is essential for opti-
mal tyrosine phosphorylation, activation of PLC- 1 and
PLC- 2, and, thus, for calcium mobilization (13). To ex-
plore which tyrosine residues in LAT bind PLC- 1 and
PLC- 2, these proteins were immunoprecipitated from ac-
tivated, reconstituted LAT /  BMMCs with anti–PLC- 1
and anti–PLC- 2 antibodies. As shown in Fig. 3 (B and C),
tyrosine phosphorylation of PLC- 1 and PLC- 2 was de-
tected by antiphosphotyrosine blotting and LAT associa-
tion was determined. PLC- 1 was tyrosine phosphorylated
in cells expressing LAT-WT after stimulation. Tyrosine
phosphorylation of PLC- 1 in infected BMMCs express-
ing LAT-2YF was decreased by  50%. Tyrosine phos-
phorylation of PLC- 1 in cells expressing LAT-1YF,
LAT-3YF, or LAT-4YF was detected at a level comparable
to cells not expressing any LAT (CD2 only) or LAT / 
BMMC. In this experiment, LAT coprecipitation with
PLC- 1 was difficult to detect and was only seen in cells
expressing LAT-WT or LAT-2YF. The subtle defect in
PLC phosphorylation in the 2YF, which might be more
impressive were it not for the twofold-higher level of pro-
tein expression (Fig. 2 C) and the more complete block in
the 3YF, indicates that, in addition to the predicted PLC- 
site at Y136, the Grb2-binding sites in LAT are also essen-
tial for PLC- 1. In similar experiments, LAT coprecipita-
tion with PLC- 2 was difficult to detect (unpublished
data). However, results qualitatively similar to those seen
with PLC- 1 were seen when tyrosine phosphorylation of
PLC- 2 was measured in cells expressing the various LAT
mutants. From these results, it is clear that phosphorylation,
and, thus, activation of both PLC isoforms is dependent on
the same LAT tyrosine residues.
That the association of PLC isoforms with LAT also de-
pends on Grb2-binding sites may reflect the observations
made in T cell systems that the adaptor SLP-76 is also re-
quired for LAT interaction with PLC. SLP-76 is brought
to LAT via the interaction of Gads, a Grb2-related protein
(21, 22). Gads-binding sites on LAT include, at least, Tyr
Figure 2. Surface expression
level of rat CD2, IgE receptor,
and LAT expression level in
BMMCs from LAT / , LAT / ,
and LAT /  mice and in the
LAT /  BMMCs infected with
retrovirus. (A) Rat CD2 expres-
sion level. BMMCs were treated
with FITC-conjugated anti–rat
CD2 (continuous line) or FITC-
conjugated IgG as negative con-
trol (dotted line). The rat CD2
expression level on noninfected
LAT /  BMMCs was basal level
(continuous line). (B) IgE recep-
tor expression level. BMMCs
were treated with anti-DNP IgE
mAb after anti-CD16/CD32
treatment, and incubated with
FITC-conjugated rat anti–mouse
IgE. Control staining was with
FITC-conjugated rat anti–mouse
IgE alone (dotted line). (C)
BMMCs were fixed with 3.7%
paraformaldehyde for 30 min
and treated with 0.1% Triton
X-100 for 4 min. After blocking
with 2% goat serum, BMMCs
were stained with anti-LAT anti-
serum and phycoerythrin-conju-
gated goat anti–rabbit antibody.
LAT expression level in BMMCs was divided into four different peaks. Peak 1 shows LAT expression level of the infected CD2-IRES-LAT-1YF, 2YF,
3YF, 4YF, and WT BMMCs. Peak 2 shows LAT expression level of LAT /  BMMCs. Peak 3 shows LAT expression level of LAT /  BMMCs. Peak
4 shows LAT expression level of LAT /  BMMCs and cells expressing CD2-IRES. (D) Proteins in whole cell lysates from 2   105 BMMCs were sep-
arated by SDS-PAGE, and immunoblotted with anti-LAT antiserum.T
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175 and 195 (10). In this model, cooperative binding
events occur and PLC binds LAT both directly and indi-
rectly via SLP-76 (23). In a previous work, we reported
that phosphorylation of SLP-76 was decreased in LAT / 
BMMCs after Fc RI engagement (13). To demonstrate
SLP-76 phosphorylation in the infected BMMCs, SLP-76
was immunoprecipitated with anti–SLP-76 antibody after
activation. We observed a robust phosphorylation of SLP-
76 molecule in LAT-WT expressing infected BMMCs af-
ter 1-min stimulation (Fig. 3 D). Loss of two Grb2 and
Gads-binding sites in LAT-2YF cells resulted in a 50–55%
decrease in SLP-76 phosphorylation (specific activity of
phosphorylation), and loss of all three Grb2 and Gads-
binding sites in LAT-3YF cells resulted in a decrease of
SLP-76 tyrosine phosphorylation of  87%. Removal of
the PLC-binding site also had an effect. SLP-76 phosphor-
ylation decreased by  70% in LAT-1YF cells compared
with that in LAT-WT expressing BMMCs. Removal of
all four distal tyrosines resulted in nearly complete loss of
SLP-76 tyrosine phosphorylation in LAT-4YF and CD2
only expressing infected LAT /  BMMCs cells. These re-
sults are compatible with the aforementioned idea of co-
operative binding.
The Role of LAT Tyrosines in Calcium Mobilization and De-
granulation. Elevation of intracellular calcium is a well-
known consequence of Fc RI stimulation. To test the ef-
fect of LAT mutations on calcium mobilization in mast
cells after Fc RI stimulation, the reconstituted BMMCs
were loaded with the calcium-sensitive dyes Fluo-4–AM
and Fura red-AM. The data shown in Fig. 4 compare the
calcium response of each reconstituted cell type compared
with LAT /  and LAT /  BMMCs. It should be noted
that, as demonstrated previously, LAT /  BMMCs show a
modest calcium response. Reconstitution of LAT / 
BMMCs with LAT-WT restored virtually normal calcium
responses. Expression of LAT-2YF and LAT-3YF resulted
in a partial calcium response. Cells expressing the point
mutation at Y136 demonstrated a much lower calcium re-
sponse. Loss of all four distal tyrosines had a major inhibi-
tory effect, and the resulting calcium response was compa-
rable to the LAT /  cells and those expressing only the
control CD2 marker (unpublished data). In this experi-
ment, the calcium responses after 1- M thapsigargin stim-
ulation were comparable in all cells (unpublished data).
The responses to Fc RI aggregation support the conclu-
sion that the Y136 site is most important for the calcium
Figure 3. Protein tyrosine phosphorylation of LAT, PLC- 1, PLC- 2, and SLP-76 in BMMCs after antigen stimulation. BMMCs were sensitized
with 1  g/ml anti-DNP IgE and stimulated with 100 ng/ml DNP-HSA for 1 min. Lysates (2–4   107 cells) were immunoprecipitated with anti-LAT
(A), anti–PLC- 1 (B), anti–PLC- 2 (C), anti–SLP-76 (D). Immunoprecipitated proteins were resolved by electrophoresis and transferred to nitrocellu-
lose membranes. (A) Tyrosine phosphorylation of LAT and Grb2 association with LAT. After LAT immunoprecipitation, the membrane was immunoblotted
with antiphosphotyrosine and anti-Grb2 antibody, and after stripping was reblotted with anti-LAT antiserum. (B) Tyrosine phosphorylation of PLC- 1
and association of PLC- 1 and LAT. After PLC- 1 immunoprecipitation, the membrane was immunoblotted with antiphosphotyrosine, and after strip-
ping, it was reblotted with anti–PLC- 1. (C) Tyrosine phosphorylation of PLC- 2 and association PLC- 2 and LAT. After PLC- 2 immunoprecipita-
tion, the membrane was immunoblotted with antiphosphotyrosine, and after stripping, it was reblotted with anti–PLC- 2. (D) Tyrosine phosphorylation
of SLP-76. After SLP-76 immunoprecipitation the membrane filter was immunoblotted with antiphosphotyrosine, and after stripping, it was reblotted
with anti–SLP-76. Representative data from three or four independent experiments are shown.T
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response, but a supportive role is played by the three other
distal tyrosines. These functional results are consistent with
aforementioned evidence revealing the cooperative inter-
actions required for PLC binding and phosphorylation.
Continuing the functional analysis of the cells expressing
LAT mutations, we analyzed mast cell degranulation using
the  -hexosaminidase release assay (Fig. 5). Again, for the
various reconstituted cells, degranulation was compared
with LAT /  and LAT /  BMMCs. LAT-WT fully re-
constituted LAT /  BMMCs. The degranulation of cells
expressing LAT-2YF and LAT-3YF was partially inhibited.
In contrast the LAT-1YF, LAT-4YF and control cells (un-
published data) released  -hexosaminidase at the same level
as LAT /  BMMCs. Thapsigargin stimulation–induced
degranulation was comparable in all infected BMMCs and
noninfected BMMCs (unpublished data). Consistently in
the assays described in Figs. 3 and 4, the loss of the four dis-
tal tyrosines ablates a response. In degranulation, the loss of
the primary PLC-binding site alone is equally destructive.
Regulation of MAP Kinases via the Four Distal Tyrosines of
LAT. MAP kinase activation is central to transcriptional
activation of cytokines and chemokines in mast cells. We
reported previously that mast cells deficient in LAT dem-
onstrated impaired ERK and JNK activation (13). JNK1
activation in the reconstituted BMMCs was measured by in
vitro kinase assay using c-Jun–GST as a substrate. As shown
in Fig. 6 A, JNK1 activation in BMMCs expressing LAT-
WT was robust and comparable or greater than in LAT / 
BMMCs. JNK1 activation was comparable in cells express-
ing LAT-4YF and LAT /  BMMCs. JNK1 activation was
not fully reconstituted by expression of any of the four mu-
tant LAT constructs. JNK1 activation in cells expressing
LAT-2YF was decreased by 55–60% compared with those
cells with LAT-WT. JNK1 activation in cells expressing
LAT-1YF and LAT-3YF was decreased by  78%. JNK1
activation in BMMCs with LAT-4YF was decreased by
90%. These results demonstrate that the four distal tyrosines
are critical for JNK1 activation and that both the Y136-
binding site and the three Grb2-binding sites are essential
for JNK1 activation after Fc RI engagement.
To detect ERK activity in the BMMCs, ERK2 was im-
munoprecipitated from LAT /  BMMCs, LAT / 
BMMCs and the reconstituted BMMCs. ERK2 activity
was measured by in vitro kinase assay using MBP as a sub-
strate (Fig. 6 B). LAT-WT reconstituted the LAT /  cells.
Reconstitution with the 1YF, 2YF, or 3YF constructs was
partial. Expression of the LAT-4YF construct failed to re-
constitute ERK2 activation to a level higher than seen in
control reconstituted cells. As shown in Fig. 6 C, activated
p38 was detected by blotting lysates with a specific anti-
phospho–p38 antibody. An increase in phosphorylation of
the p38 kinase was observed in activated LAT /  BMMCs
as well as BMMCs expressing LAT-2YF and LAT-WT.
However p38 MAP kinase phosphorylation was decreased
significantly in LAT /  BMMCs, and LAT /  cells ex-
pressing only CD2, LAT-1YF, LAT-3YF, or LAT-4YF.
Thus, for all the tested MAP kinases, complete reconstitu-
tion requires all four distal LAT tyrosine residues.
Figure 4. Ca2  mobilization in BMMCs after anti-
gen stimulation. BMMCs were sensitized with 1  g/
ml anti-DNP IgE for 6 h and loaded with Fluo-4–AM
and Fura red–AM. BMMCs were stimulated with 100
ng/ml DNP-HSA at the indicated time. Fluo-4 and
Fura red fluorescence intensity after antigen stimulation
was measured by flow cytometry. Intracellular Ca con-
centration is indicated by the ratio of Fluo-4/Fura red
fluorescence intensity. Representative data from five
independent experiments are shown.
Figure 5. The level of degranulation was determined by measuring the
release of  -hexosaminidase. 2   106/ml BMMCs were sensitized for 6 h
with 1  g/ml anti-DNP IgE in medium (without IL-3), and stimulated
with the indicated concentration of DNP-HSA or 1 mM thapsigargin for
7 min in Tyrode’s buffer.  -Hexosaminidase enzymatic activity was mea-
sured in supernatants and cell pellets solubilized with 0.5% Triton X-100
in Tyrode’s buffer. Total percentage of the  -hexosaminidase release was
calculated by dividing absorbance in the supernatant by the total absor-
bance in the supernatants plus cell pellets. Standard errors reflect three ex-
periments. Spontaneous release ranged from 8.7 to 12%.T
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Cytokine and Chemokine Expression Are Regulated by the
Predicted PLC- 1– and Grb2-binding Sites in the Distal Four
Tyrosines of LAT. To detect cytokine and chemokine
mRNA expression after Fc RI engagement, BMMCs
were stimulated with 100 ng/ml DNP-HSA for 60 min.
RNA purified from the BMMCs was analyzed by RT-
PCR for IL-2 detection or by RNA protection assay using
specific primers or probes. Seven cytokines (IL-1 , IL-2,
IL-6, IL-13, LIF, M-CSF, and TNF- ) and five chemo-
kines (MCP-1, MIP-1 , MIP-1 , RANTES, and TCA3)
were evaluated (Fig. 7). By comparing the response of
LAT /  cells reconstituted with WT or the four mutant
forms of LAT, three qualitative patterns of response were
detected. For all but two of the products (IL-1  and MCP-
1), a similar hierarchy of response was observed. For all of
these chemokines and cytokines, the analysis revealed the
same hierarchy of mutant effects: 2YF   3YF   1YF  
4YF. The effect of the loss of two or three of the Grb2-
binding sites was less than the effect of losing Y136. The
loss of all four distal tyrosines was most pronounced, and
was roughly comparable to the LAT /  cells. Within this
order of response however, the actual level of activity var-
ied from nearly complete LAT dependence (RANTES and
IL-2) to examples in which the response was nearly half
that of the LAT /  cells (MIP-1  and TCA3).
The analysis of IL-1  production showed a slightly dif-
ferent phenotype. In this case the effects of the 2YF and
3YF mutations was greater than that of the 1YF, suggest-
ing more of a role for pathways coupled to Grb2 or related
molecules compared with PLC. Nonetheless, expression
of the 4YF mutation did bring the level of cytokine pro-
duction down to that produced by the LAT /  cells. Fi-
nally, analysis of MCP-1 production revealed virtually no
role for LAT. There was no difference in expression be-
tween the LAT /  and LAT /  cells, and, thus, the ex-
pression of the various LAT mutations did not affect levels
of MCP-1 production.
Passive Systemic Anaphylaxis in Mice with LAT Muta-
tions. The preceding series of experiments provide further
evidence of the function of LAT in various signaling cas-
cades and cellular responses in BMMC. Reconstitution
with the various LAT mutants confirm the importance of
these sites in the signal transduction process. To analyze the
function of these LAT tyrosine residues in the intact ani-
Figure 6. MAP kinase activity in BMMCs after anti-
gen stimulation. (A and B) ERK and JNK activities in
BMMCs after antigen stimulation. BMMCs were sensi-
tized with 1  g/ml anti-DNP IgE and stimulated with
100 ng/ml DNP-HSA for 10 min. (A) JNK1 kinase ac-
tivity was measured by in vitro kinase assay. (top) An
autoradiograph of 32P-incorporated into c-Jun–GST
after its phosphorylation by JNK1 immunoprecipitates
from BMMCs. The same filter was probed with an
anti-JNK1 antibody. (bottom) The JNK1 protein
amount is shown. (B) ERK2 kinase activity was mea-
sured by in vitro kinase assay. (top) An autoradiograph
of  32P-incorporated into myelin basic protein (MBP)
after its phosphorylation by ERK2 immunoprecipitates
from BMMCs. (bottom) The amount of ERK2 protein
in the same cell lysates by anti-ERK2 immunoblot.
(C) p38 phosphorylation in BMMCs after antigen
stimulation. BMMCs were sensitized with 1  g/ml
anti-DNP IgE and stimulated with 100 ng/ml DNP-
HSA for 5 and 10 min. Proteins in cell lysates from 2  
105 BMMCs were separated by SDS-PAGE, and were
transferred to nitrocellulose membrane filters. The
membrane was immunoblotted with anti–phospho-p38
antibody. After stripping, the same membrane was immu-
noblotted with anti-p38. Representative data from
three independent experiments are shown.T
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mal, we used an assay for passive systemic anaphylaxis.
Normal mice were pretreated with monoclonal anti-DNP
IgE and challenged with polyvalent DNP-HSA to aggre-
gate mast cell Fc RI. A massive histamine release can be
measured minutes after antigen delivery. In a previous pa-
per (13), we showed that LAT-deficient mast cells failed to
release histamine under these conditions. In the current
analysis, the wild-type response was compared with two
mice in which LAT mutations that showed the most pro-
nounced defect in PLC binding replaced the wild-type
LAT allele (18, 24). Mice lacking all four distal LAT tyro-
sines showed a marked decrease in histamine release after
Figure 7. Expression of cyto-
kine and chemokine mRNAs after
antigen stimulation in BMMCs.
(A) 2   106 BMMCs were sensi-
tized with 1  g/ml anti-DNP
IgE and stimulated with 100 ng/
ml DNP-HSA for 1 h. mRNA
was purified from BMMCs, and
cytokine mRNAs, except for
IL-2, were detected by RNA
protection assay using specific
primers or template sets for each
cytokine. IL-2 results were ob-
tained by RT-PCR. (B) Che-
mokine mRNAs were also de-
tected with RNA protection
assay. Standard errors in RNA
protection assays reflect three to
five experiments.T
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administration (Fig. 8). Mice expressing only LAT protein
with the Y136F (1YF) mutation showed no measurable
histamine release.
Mice expressing the Y136F mutation exhibit a lympho-
proliferative disorder characterized by expansion of CD4 
T cells that elaborate Th2 lymphokines (24). One of many
consequences is that levels of circulating IgE are very high.
Such IgE could saturate mast cell Fc RI, thereby blocking
the binding of the anti-DNP IgE and preventing mast cell
activation via multivalent antigen. To bypass that possibil-
ity, WT and 1YF mice were infused with IgE and treated
with anti-IgE as a cross-linking reagent. Mast cells from
anti-IgE–treated WT mice release histamine at levels com-
parable to antigen-treated mice. In contrast, cross-linked
mast cells in the 1YF mice fail to release significant
amounts of histamine. This result demonstrates the critical
function of the LAT Y136 residue in vivo.
Discussion
Aggregation of the Fc R1 leads to activation of multiple
PTKs and subsequent phosphorylation of adaptor mole-
cules capable of recruiting multiple signaling molecules (1,
25, 26). Much effort has been directed at characterization
of one such pathway dependent on Lyn, Syk, and the
phosphorylation of the adaptor molecules, LAT and SLP-
76 (4, 13, 27, 28). The significance of this pathway has
been confirmed by the significant defects in mast cell acti-
vation that follows genetic disruption of genes encoding
these molecules (7, 13, 29, 30). However, a number of pa-
pers demonstrate that loss of one of these signaling mole-
cules does not ablate mast cell signaling completely. As an
example, our previous work documenting the essential role
of LAT in mast cell signaling still provided evidence that
LAT /  mast cells had partial, residual function (13). Re-
cent analyses provide evidence for an alternative signaling
pathway in mast cells. The adaptor molecule Gab2 has
been shown to be critical to mast signaling due to its ability
to recruit PI-3 kinase (31). Gab2 phosphorylation and,
thus, its ability to recruit additional molecules appears to be
dependent on the Fyn PTK (32). Our current studies focus
primarily on LAT-associated pathways, which we demon-
strate to be complex and interactive.
Previous studies in T cells demonstrated that all four dis-
tal tyrosines of LAT were necessary for optimal signaling
(10). These studies, performed in LAT-deficient Jurkat
cells, showed that cells reconstituted with a mutant lacking
these four residues failed to signal at all. The work also
confirmed that the distal three tyrosine residues bind Grb2
and that residues homologous to Tyr 175 and 195 are the
primary sites of Gads–SLP-76 binding. PLC- 1 binding
and activation in Jurkat cells was primarily dependent on
the site homologous to the murine Y136 site, but both
binding and activation were decreased in cells reconstituted
with the LAT-3YF mutation. LAT mutations have also
been introduced into the murine genome, and the subse-
quent effects on T cell development, also a LAT-depen-
dent process, have been studied. No T cell development
occurs in LAT /  mice nor in mice expressing only the
LAT 4YF mutation (14, 18). Thymocytes of mice express-
ing only the LAT-1YF mutation are defective in their abil-
ity to flux calcium. These mice develop an interesting lym-
phoproliferative and autoimmune phenotype (24, 33).
The current studies were initiated in an attempt to fur-
ther define the role of LAT in mast cell function. LAT-
dependent binding and signaling were assayed in mast cells
derived from WT or LAT /  mice or from LAT /  mast
cells reconstituted using retroviral vectors with one of four
LAT mutants. Coimmunoprecipitation studies were used
to test the effects of these mutations. The detection of a
coimmunoprecipitated protein was difficult, and in our ex-
periments, presence of the more easily detected phospho-
protein was used as evidence for binding. In coprecipitation
studies, loss of the Y136 site had no effect on Grb2 binding,
as expected. However, the other binding studies showed
some indication of more complex interactions. Coprecipi-
tation with LAT of phosphorylated forms of two PLC iso-
forms and SLP-76 was affected both by loss of the Y136 site
as well as loss of the three Grb2-binding sites. The loss of all
four tyrosines resulted in a further decrease in coprecipi-
tated phosphorylated protein. Evidence that multiple tyro-
sines on LAT regulate binding of PLC and SLP-76 is con-
sistent with evidence in T cells that binding of Gads, SLP-76,
and PLC  is highly cooperative (23). In this model, both
Gads and PLC bind LAT directly and additional evidence
for SLP-76/PLC -binding has been provided.
Our functional experiments provide further support for
the role of protein interaction at LAT. Both calcium flux,
which is dependent on PLC binding and activation, as well
as degranulation are highly dependent on LAT. No recon-
stitution of the response in LAT / mast cells is shown
when cell expressing LAT-4YF were tested, indicating that
the role of LAT in these functions is wholly dependent on
these tyrosines. Partial reconstitution is observed with the
other LAT mutants (1YF, 2YF, and 3YF). The calcium re-
sponse is more dependent on Y136, but loss of the Grb2-
or Gads-binding sites has an effect supporting the afore-
mentioned model of complex interactions. Similar results
Figure 8. Mice were sensitized and challenged as described in Materials
and Methods. The serum histamine levels of four or six mice of the indi-
cated genotype either pseudochallenged or challenged with DNP-HSA
or anti-IgE is shown. The median responses are indicated by the horizon-
tal lines.T
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are found with degranulation, though the 1YF mutation
was essentially identical to LAT /  and 4YF mutants.
These data may reflect the added complexity that degranu-
lation is dependent both on calcium flux as well as other
signaling pathways. It is possible that ERK is coupled to
LAT by virtue of Grb2 recruiting the activator SOS, but as
is true in T cells, additional Ras GEFs such as RasGRP
may be involved (34–37). JNK and p38 are also known to
be activated by a cascade of proximal serine/threonine ki-
nases, but the actual means of coupling these cascades to
LAT is not known. Regardless, the LAT dependence of all
of these pathways also seems complex and similar to the
pathways described in Figs. 3–5. All the LAT-4YF is most
strongly inhibited whereas the other mutants provide only
partial reconstitution.
We demonstrated recently that weak stimulation of
Fc RI caused a stronger induction of Fyn/Gab2- versus
LAT-mediated signaling and skewed the lymphokine re-
sponse toward a more potent chemokine response (38).
Analysis, under weak stimulation, of mast cells from gene-
inactivated mice showed a difference in the relative impor-
tance of Gab2 or LAT for chemokines or cytokines, re-
spectively. This difference was narrowed when the stimulus
strength was increased. However, consistent with the
present results, MCP-1 mRNA was relatively unaffected
by LAT deficiency, regardless of stimulus strength. In con-
trast, Gab2 was required for a normal MCP-1 response.
The transcriptional events we measured in the present
work demonstrate still further complexity. Evidence for at
least partial LAT dependence is observed for nearly all lym-
phokines when a strong stimulus is used. Again, wherever a
role for LAT was shown, the 4YF mutation ablated all
LAT-dependent effects. The other three mutations had less
effect. These results offer further evidence for the idea that
multiple pathways converge at LAT and that these interac-
tions are needed for optimal response.
BMMCs were used as a means to study the effects of
LAT tyrosine mutations on signaling and cellular events that
follow Fc RI engagement. As noted, these tyrosine residues
are critical to these pathways and to mast cell activation.
However, it is difficult to judge the significance of some of
the quantitative differences between cells expressing the
various sets of mutations. To more critically evaluate the
function of the distal four tyrosines and the Y136F muta-
tion, in particular, we decided to determine the effect of
these mutations on in vivo histamine release. Previous work
had revealed the requirement for LAT in this pathophysio-
logic response (13). The experiments described in this paper
indicate that the mice bearing either the 4YF or the 1YF
LAT mutations are severely compromised in the passive sys-
temic anaphylaxis response. In view of the high level of
circulating IgE observed in the 1YF mouse, anti-IgE cross-
linking was used as a means of bypassing potentially satu-
rated receptors. The response was the same under these
conditions. In view of the fact that these mice are systemi-
cally ill, a reasonable caveat for this result is that there may
be other unknown factors contributing to the complete ab-
sence of response. The low level of histamine release in
some of the 4YF mice does suggest that there may be some
compensatory mechanism in these mice, but not in the to-
tally LAT-deficient mice that allow for some response.
In addition to our work with LAT-deficient BMMCs,
works on the function of BMMCs deficient in SLP-76,
Vav, and Gab2 have been published. The phenotype of the
LAT- and SLPL-76–deficient mast cells are nearly identi-
cal, suggesting, as suspected, that these molecules lie in the
same pathway (13, 30). In Vav-deficient cells, most re-
sponses are similar to LAT-deficient cells, but degranula-
tion, systemic anaphylaxis, and IL-3 expression were not as
severely compromised in Vav-deficient cells (39). TNF 
expression and ERK activation were not significantly af-
fected and PI3 kinase activation was more affected in the
Vav-deficient cells. The general similarity of response in
these cells suggests that Vav and LAT are in the same path-
way for many responses but are independent for others.
Some of the loss of Vav effects are also observed in Gab2-
deficient cells, which differ most notably from LAT-defi-
cient cells in that Gab2 is required for a PI3 kinase response
whereas loss of LAT has no effect on the PI3 kinase path-
way (31). JNK and p38 kinases are more adversely affected
by loss of Gab2 than by loss of LAT. The results from these
various studies indicate that several pathways are coupled to
the Fc R1. These include Gab2- and LAT-coupled re-
sponses (32). Additionally, our current work demonstrates
the interaction of pathways coupled via different tyrosine
residues on LAT. More detailed understanding of these
various pathways will require careful analysis of BMMCs
designed to be deficient in multiple adapters and signaling
molecules.
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